Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

RCT (n=143) found addition of subcutaneous nemolizumab (monoclonal antibody against IL-31 receptor A) to plus topical agents, resulted in greater reduction in pruritus vs. placebo at week 16 (mean change VAS score−42.8 vs−21.4%;p<0.001) but linked to more injection-site reactions


New England Journal of Medicine